Fractional CFO Services for Biotechnology Companies

1. Why Biotech Finance Is Different

Most businesses generate revenue and manage costs against it. Biotechnology companies often spend years — sometimes a decade or more — investing heavily in R&D before generating meaningful revenue, funded instead by a mix of equity, grants, and refundable tax credits. That fundamentally changes what financial leadership needs to look like:

• Non-dilutive funding is a core strategy, not a bonus: SR&ED credits, IRAP funding, and provincial grants can meaningfully extend runway without giving up equity.
• Burn rate is the central metric: Unlike a revenue-generating business tracking margin, a pre-revenue biotech's most important number is how many months of cash remain.
• Accounting complexity is high: R&D expenditure classification, grant accounting, licensing and collaboration agreements, and milestone-based revenue recognition all require specialized treatment.
• Investor scrutiny is intense: Biotech investors expect founders to defend their burn rate, runway, use of proceeds, and development assumptions in detail.

A generalist bookkeeper or accountant can keep the books technically accurate, but rarely has the depth to manage this stack of funding sources, accounting complexity, and investor expectations at the same time — which is exactly the gap a biotech-experienced fractional CFO fills.

2. The Canadian Biotech Funding Stack

Canada treats biotechnology and life sciences as a high-priority sector, and the federal government offers substantial support across multiple programs. The most effective biotech companies stack several of these on the same project, up to an overall government-assistance cap:

SR&ED must be claimed with the T2 corporate return within 18 months of year-end — missed deadlines forfeit the claim. IRAP and other direct grants generally reduce the SR&ED-eligible expenditure base dollar-for-dollar, so the funding stack needs to be structured deliberately rather than layered on ad hoc.

Illustrative figures based on the 35% enhanced refundable rate for eligible CCPCs; actual eligibility and amounts depend on corporate structure and qualifying expenditures.

3. Core Fractional CFO Deliverables for Biotech

A biotech-experienced fractional CFO's work typically centers on these deliverables:

• SR&ED identification and documentation systems: Building the contemporaneous technical documentation CRA requires — time logs, experiment records, and technical reports created during the year, not reconstructed afterward.
• Grant and blended funding coordination: Structuring financial projections that satisfy both grant program requirements and investor expectations simultaneously.
• 13-week rolling cash flow forecasting: Weekly cash position tracking against the realistic timeline of R&D milestones and funding events.
• Investor-grade financial models: Multi-year P&L, balance sheet, and cash flow projections built from operational assumptions, with base, bull, and bear scenarios.
• Board and investor reporting: KPI dashboards that reflect R&D milestone progress, burn rate, and runway — not just standard revenue metrics.
• Equity compensation structuring: Navigating stock option and RSU structures that are standard in the sector for attracting scientific talent.

4. Complex Accounting Areas a Biotech CFO Manages

Biotech companies routinely face accounting questions that a generalist bookkeeper isn't equipped to handle correctly:

• R&D expenditure classification: Determining what qualifies as SR&ED-eligible versus routine development work.
• Grant and government assistance accounting: Properly recognizing grants and refundable credits under the applicable accounting framework (ASPE or IFRS).
• Licensing and collaboration agreements: Structuring the accounting treatment for out-licensing, in-licensing, and co-development partnerships.
• Milestone-based revenue recognition: Recognizing partnership or licensing revenue tied to development, regulatory, or commercial milestones.
• Equity compensation: Valuing and accounting for stock options and other equity awards common in scientific talent recruitment.

5. Burn Rate and Runway Management

For a pre-revenue or early-revenue biotech, burn rate and runway are the metrics that determine survival. A fractional CFO's core discipline here includes:

• Weekly cash position tracking: Not monthly — biotech burn moves fast enough that weekly visibility matters.
• Burn rate optimization: Identifying non-essential spend without compromising the R&D timeline that drives valuation.
• Runway-to-milestone alignment: Ensuring cash on hand comfortably covers the time needed to reach the next value-inflection milestone (a data readout, regulatory filing, or partnership event) before the next raise is needed.
• Scenario planning: Modeling best-case, base-case, and worst-case runway scenarios so the board isn't surprised by a shortfall.

Illustrative planning benchmarks — the right runway target depends on your specific development timeline and upcoming milestone events.

6. Investor Readiness and Fundraising Support

Biotech investors expect more than historical financial statements — they want to understand the assumptions behind your numbers and see that management can defend them. A fractional CFO prepares a company for this by building:

• An integrated financial model: Multi-year P&L, balance sheet, and cash flow projections tied directly to R&D milestones and hiring plans.
• A defensible use-of-proceeds narrative: Clear mapping of how raised capital will be deployed against the development timeline.
• A due diligence-ready data room: Financial statements, cap table, grant documentation, and SR&ED history organized and accessible.
• Board-level KPI reporting: Consistent reporting that builds investor confidence between formal fundraising events.

The typical engagement roadmap

1. Step 1 — Financial and funding diagnosticReview current financials, funding sources claimed and unclaimed, and reporting gaps.
2. Step 2 — Build the SR&ED and grant documentation systemSet up contemporaneous tracking so future claims are defensible and maximized.
3. Step 3 — Establish burn rate and runway reportingWeekly cash tracking and a rolling 13-week forecast tied to milestones.
4. Step 4 — Build the investor-grade financial modelMulti-year projections with scenario planning for fundraising conversations.
5. Step 5 — Ongoing board and investor reportingRecurring KPI dashboards and monthly reviews that keep the company fundraising-ready year-round.

7. What It Costs

Fractional CFO pricing for biotech companies varies significantly based on funding stage, R&D complexity, and whether active fundraising is underway.

Complexity — not just revenue or funding stage — drives pricing. A company with SR&ED claims, multiple grant programs, and licensing agreements typically needs more CFO hours than a similarly sized company without that complexity.

Related reading from our team

8. Frequently Asked Questions

9. How Custom CPA Can Help

Biotech companies need financial leadership that understands both the science-driven funding landscape and the accounting complexity that comes with it. Our team supports Canadian biotechnology and life sciences companies with:

• Core accounting, tax compliance, and SR&ED claim support
• Strategic CFO advisory built for R&D-driven companies
• Specialized industry accounting and compilation services
• Business planning and financial modeling for fundraising and grant applications